4-Quinolone-3-Carboxamide CB2 Ligand – 25 mg

Brand:
Cayman
CAS:
1314230-69-7
Storage:
-20
UN-No:
Non-Hazardous - /

Cannabinoids (CBs) and their synthetic analogs produce biochemical and pharmacological effects by interacting with the central CB1 and peripheral CB2 receptors. The CB2 receptor has emerged as a pharmacotherapeutic target for treating osteoporosis, as well as for eliciting antinociceptive effects in various models of pain. 4-Quinolone-3-carboxamide CB2 ligand is a selective, high-affinity ligand of the CB2 receptor, displaying a Ki value of 0.6 nM (Ki >10,000 nM for CB1) in vitro. At a dose of 6 mg/kg, 4-quinolone-3-carboxamide CB2 ligand exhibits antinociceptive activity in a formalin test of nocifensive response in mice. This analgesic affect is not significantly reversed by the CB2 antagonist AM630 (Item No. 10006974), which suggests 4-quinolone-3-carboxamide CB2 ligand may behave as an inverse agonist.{20020}  

 

Available on backorder

SKU: 11093 - 25 mg Category:

Description

A selective, high-affinity ligand of the CB2 receptor (Ki = 0.6 nM v. CB1 binding at a Ki >10,000 nM in vitro) that may behave as an inverse agonist; displays antinociceptive activity in a formalin test in mice at a dose of 6 mg/kg


Formal name: 1,4-dihydro-8-methoxy-4-oxo-1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-3-quinolinecarboxamide

Synonyms:  4Q3C CB2 Ligand

Molecular weight: 422.6

CAS: 1314230-69-7

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Pain Research